329 related articles for article (PubMed ID: 31718149)
1. SAR by (Protein-Observed)
Divakaran A; Kirberger SE; Pomerantz WCK
Acc Chem Res; 2019 Dec; 52(12):3407-3418. PubMed ID: 31718149
[TBL] [Abstract][Full Text] [Related]
2. Fragment screening and druggability assessment for the CBP/p300 KIX domain through protein-observed 19F NMR spectroscopy.
Gee CT; Koleski EJ; Pomerantz WC
Angew Chem Int Ed Engl; 2015 Mar; 54(12):3735-9. PubMed ID: 25651535
[TBL] [Abstract][Full Text] [Related]
3. Fluorinated aromatic amino acids are sensitive 19F NMR probes for bromodomain-ligand interactions.
Mishra NK; Urick AK; Ember SW; Schönbrunn E; Pomerantz WC
ACS Chem Biol; 2014 Dec; 9(12):2755-60. PubMed ID: 25290579
[TBL] [Abstract][Full Text] [Related]
4. Protein-observed (19)F-NMR for fragment screening, affinity quantification and druggability assessment.
Gee CT; Arntson KE; Urick AK; Mishra NK; Hawk LM; Wisniewski AJ; Pomerantz WC
Nat Protoc; 2016 Aug; 11(8):1414-27. PubMed ID: 27414758
[TBL] [Abstract][Full Text] [Related]
5. Profiling the dynamic interfaces of fluorinated transcription complexes for ligand discovery and characterization.
Pomerantz WC; Wang N; Lipinski AK; Wang R; Cierpicki T; Mapp AK
ACS Chem Biol; 2012 Aug; 7(8):1345-50. PubMed ID: 22725662
[TBL] [Abstract][Full Text] [Related]
6. Dual Screening of BPTF and Brd4 Using Protein-Observed Fluorine NMR Uncovers New Bromodomain Probe Molecules.
Urick AK; Hawk LM; Cassel MK; Mishra NK; Liu S; Adhikari N; Zhang W; dos Santos CO; Hall JL; Pomerantz WC
ACS Chem Biol; 2015 Oct; 10(10):2246-56. PubMed ID: 26158404
[TBL] [Abstract][Full Text] [Related]
7. Dual Labeling of the CBP/p300 KIX Domain for
Gee CT; Arntson KE; Koleski EJ; Staebell RL; Pomerantz WCK
Chembiochem; 2018 May; 19(9):963-969. PubMed ID: 29430847
[TBL] [Abstract][Full Text] [Related]
8. Protein-Observed Fluorine NMR Is a Complementary Ligand Discovery Method to
Urick AK; Calle LP; Espinosa JF; Hu H; Pomerantz WC
ACS Chem Biol; 2016 Nov; 11(11):3154-3164. PubMed ID: 27627661
[TBL] [Abstract][Full Text] [Related]
9. New inhibitors for the BPTF bromodomain enabled by structural biology and biophysical assay development.
Ycas PD; Zahid H; Chan A; Olson NM; Johnson JA; Talluri SK; Schonbrunn E; Pomerantz WCK
Org Biomol Chem; 2020 Jul; 18(27):5174-5182. PubMed ID: 32588860
[TBL] [Abstract][Full Text] [Related]
10. Combined Protein- and Ligand-Observed NMR Workflow to Screen Fragment Cocktails against Multiple Proteins: A Case Study Using Bromodomains.
Johnson JA; Olson NM; Tooker MJ; Bur SK; Pomerantz WCK
Molecules; 2020 Aug; 25(17):. PubMed ID: 32872491
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the Advantages of Using 3D-Enriched Fragments for Targeting BET Bromodomains.
Johnson JA; Nicolaou CA; Kirberger SE; Pandey AK; Hu H; Pomerantz WCK
ACS Med Chem Lett; 2019 Dec; 10(12):1648-1654. PubMed ID: 31857841
[TBL] [Abstract][Full Text] [Related]
12. NMR-based platform for fragment-based lead discovery used in screening BRD4-targeted compounds.
Yu JL; Chen TT; Zhou C; Lian FL; Tang XL; Wen Y; Shen JK; Xu YC; Xiong B; Zhang NX
Acta Pharmacol Sin; 2016 Jul; 37(7):984-93. PubMed ID: 27238211
[TBL] [Abstract][Full Text] [Related]
13. 2-Fluorotyrosine is a valuable but understudied amino acid for protein-observed
Ycas PD; Wagner N; Olsen NM; Fu R; Pomerantz WCK
J Biomol NMR; 2020 Jan; 74(1):61-69. PubMed ID: 31760571
[TBL] [Abstract][Full Text] [Related]
14. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.
Maurer T
Methods Enzymol; 2011; 493():469-85. PubMed ID: 21371602
[TBL] [Abstract][Full Text] [Related]
15. Selectivity, ligand deconstruction, and cellular activity analysis of a BPTF bromodomain inhibitor.
Kirberger SE; Ycas PD; Johnson JA; Chen C; Ciccone MF; Woo RWL; Urick AK; Zahid H; Shi K; Aihara H; McAllister SD; Kashani-Sabet M; Shi J; Dickson A; Dos Santos CO; Pomerantz WCK
Org Biomol Chem; 2019 Feb; 17(7):2020-2027. PubMed ID: 30706071
[TBL] [Abstract][Full Text] [Related]
16. Prediction of (19)F NMR Chemical Shifts in Labeled Proteins: Computational Protocol and Case Study.
Isley WC; Urick AK; Pomerantz WC; Cramer CJ
Mol Pharm; 2016 Jul; 13(7):2376-86. PubMed ID: 27218275
[TBL] [Abstract][Full Text] [Related]
17. NMR-based screening methods for lead discovery.
Vogtherr M; Fiebig K
EXS; 2003; (93):183-202. PubMed ID: 12613177
[TBL] [Abstract][Full Text] [Related]
18. Process of Fragment-Based Lead Discovery-A Perspective from NMR.
Ma R; Wang P; Wu J; Ruan K
Molecules; 2016 Jul; 21(7):. PubMed ID: 27438813
[TBL] [Abstract][Full Text] [Related]
19. A Practical Perspective on the Roles of Solution NMR Spectroscopy in Drug Discovery.
Li Q; Kang C
Molecules; 2020 Jun; 25(13):. PubMed ID: 32605297
[TBL] [Abstract][Full Text] [Related]
20. Recent applications of isotopic labeling for protein NMR in drug discovery.
Hiroaki H
Expert Opin Drug Discov; 2013 May; 8(5):523-36. PubMed ID: 23480844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
